Clinical Trial Update: Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101) [Phase 1, Phase 2]

View source ↗

Summary

Open-label, dose-escalation study of pemigatinib in advanced malignancies (FIGHT-101) completed; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Cholangiocarcinoma
• Endometrial Cancer
• Gastric Cancer
• Lung Cancer
• Mpn
• Multiple Myeloma
• Myeloproliferative Neoplasms
• Solid Tumor
• Uc
• Urothelial Cancer

Drugs mentioned

• Pemigatinib (pemigatinib)

Snippet

Sponsor: Incyte Corporation | Conditions: Lung Cancer, Solid Tumor | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2023-01-06